Navigation Links
Celsis Introduces ReACT(TM) RNA-Based Microbial Detection Assays

Rapid, actionable intelligence in 2 hours

CHICAGO, March 27 /PRNewswire/ -- Celsis International plc (LSE: CEL.L), a global leader in rapid microbial detection solutions for industry, today announces the launch of Celsis ReACT(TM), the first easy-to-use RNA-based assay for detecting objectionable organisms quickly and definitively without the need for expensive equipment or specialized training.

Manufacturers of pharmaceutical, beauty and home care products using Celsis Rapid Detection systems for their primary screening of raw materials, in-process and finished goods can now utilize this new RNA-based assay to obtain a fast, 2-hour result on samples that test positive for microbial contamination. Celsis ReACT assays use proprietary selections of ribosomal RNA sequences to confirm or to rule out the presence of Gram-negative organisms, Staph. aureus, yeast and mold, and can be customized for facility-specific or wild strain organisms.

"Serious contamination events, while somewhat rare, do happen. When they occur they can cost companies hundreds of thousands, if not millions of dollars," explained Jay LeCoque, Celsis CEO. "We developed Celsis ReACT for our customers who have asked for a way to quickly and easily determine if they have an objectionable organism, so they can minimize the financial impact to their operations and bottom line."

The faster a company can confirm that a sample has been contaminated by an objectionable organism, the faster the contaminated batch can be stopped before it reaches the production line or, even worse, is released for sale. In addition, a faster reaction means fewer potentially contaminated additional batches will be produced, thus significantly reducing the financial impact of lost product and product disposal.

Celsis customers will be able to use Celsis ReACT following the primary Celsis AKuScreen(TM) assay, which definitively detects the presence or absence of microbial organisms in 18-24 hours instead of the typical 3-5 days for microbial limits testing. The same primary system has also been proven successful in equaling the traditional 14-day sterility test in less than half the time. Following a positive result on the Celsis primary system, the new Celsis ReACT assays use Celsis' existing instrument platform to provide rapid, actionable intelligence and secondary analysis within 2 hours.

"Celsis ReACT offers our customers the speed, simplicity and reliability of Celsis Rapid Detection systems combined with the precision of advanced molecular biology," said Lori Daane, Ph.D., a microbiologist and vice president of scientific affairs and customer service for Celsis Rapid Detection. The industry's easiest-to-use RNA system, Celsis ReACT uses simple protocols with user-friendly, color-coded steps. Basic measuring and pipetting skills are all that's required technically, and the Celsis system provides fast, clear results in two hours. With minimal training, existing customers can immediately adopt this new RNA-based testing system and begin to realize the benefits of fast, definitive results.

For more information about Celsis ReACT, visit or contact Celsis Rapid Detection at +1 312 476 1282.

About Celsis Rapid Detection Systems

Celsis Rapid Detection systems provide significant economic value to manufacturers by significantly reducing the time required to test and release raw materials, in-process solutions and finished goods to market. Pharmaceutical and consumer products manufacturers using Celsis systems realize improved cash flow and reduce their inventory and working-capital requirements, while ensuring quality and increased responsiveness throughout the supply chain.

About Celsis International plc

Celsis International plc is a leading international provider of innovative life science products and laboratory services to the pharmaceutical and consumer products industries. Each Celsis division delivers substantial time and cost savings to its customers while ensuring product quality and safety for consumers. Celsis' extensive client base includes many of the world's leading pharmaceutical and consumer products companies. The Company is listed on the London Stock Exchange (CEL.L).

Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Celsis In Vitro Technologies and Promega to Offer Fast, Reliable Solutions for ADME-Tox Testing With Primary Hepatocytes
2. Celsis Launches RapiScreen(TM) Beverage Microbial Screening System
3. Celsis Receives Frost & Sullivan 2008 Best Practices Award
4. PHARMORX Security Introduces New Technology Solutions for Counterfeiting, Grey Market Diversion, Track & Trace
5. DNA2.0 Introduces Freedom of Expression With a New Family of Bacterial Expression Vect:ors
6. Lumenis(R) Introduces Cost-Saving Innovations at the 2009 American Academy of Dermatology (AAD) Annual Meeting
7. GeneCopoeia Introduces Genome-Wide MicroRNA (miRNA) Functional Analysis Tools
8. Video: Schering-Plough Introduces AFRIN(R) PureSea(TM): A Natural, Gentle Nasal Rinse From the Seas of Northern France
9. Sigma-Aldrich Introduces MISSION(R) LentiPlex(TM) Pooled shRNA Libraries to Enable Rapid Whole Genome Screening in Primary Cells, Stem Cells or Tumor Cells
10. MaxCyte Introduces the GT(TM) Flow Transfection System for Application with Autologous and Allogeneic Stem Cell Therapies
11. Max Muscle Introduces First-Ever Probiotics Protein Bar
Post Your Comments:
(Date:6/23/2016)... Cancer Foundation (PCF) is pleased to announce 24 new Young Investigator (YI) ... of the Class of 2016 were selected from a pool of 128 applicants ... the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... STACS DNA ... Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as a ... STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further ...
(Date:6/23/2016)... 2016 Andrew D ... Published recently in ... from touchONCOLOGY, Andrew D Zelenetz , discusses ... care is placing an increasing burden on healthcare ... therapies. With the patents on many biologics expiring, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... line of intelligent tools designed, tuned and optimized exclusively for Okuma CNC machining ... Chicago. The result of a collaboration among several companies with expertise in toolholding, ...
Breaking Biology Technology:
(Date:6/16/2016)... , June 16, 2016 ... size is expected to reach USD 1.83 billion ... Grand View Research, Inc. Technological proliferation and increasing ... applications are expected to drive the market growth. ... , The development of advanced multimodal ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. and ... business relationship that includes integrating Syngrafii,s patented LongPen™ ... project. This collaboration will result in greater convenience ... credit union, while maintaining existing document workflow and ... ...
(Date:6/2/2016)... , June 2, 2016 Perimeter ... Platforms, Unmanned Systems, Physical Infrastructure, Support & Other Service  ... visiongain offers comprehensive analysis of the global ... market will generate revenues of $17.98 billion in 2016. ... DVTEL Inc, a leader in software and hardware technologies ...
Breaking Biology News(10 mins):